$SEER

Seer to Report Second Quarter 2026 Financial Results on August 11, 2026

Seer, Inc. (Nasdaq: SEER) said it will release its second-quarter 2026 financial results on Aug. 11, 2026. The company will host a webcast conference call starting 1:30 p.m. PT / 4:30 p.m. ET, with audio available on its investor website and a replay afterward.

Original reporting
Published Aug 3, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 2:25 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Seer to Report Second Quarter 2026 Financial Results on August 11, 2026 — source image
Decision brief

The 30-second read

$SEERNeutralMed
01

Why it matters

The main tradable element is the calendar catalyst for earnings, which can affect options pricing, liquidity, and short-term positioning ahead of the print.

02

Market read

Event timing matters for volatility and hedging, but the article provides no new performance data.

03

What to watch

Implied volatility may be driven more by consensus expectations and any prior quarter’s trajectory than by the mere existence of an Aug. 11 call date.

Relevance 5/10Novelty 6/10Timing: earnings event scheduled for Aug. 11, 2026

Background

Seer is a proteomics company (Proteograph Product Suite) and this release is a standard investor-relations scheduling update.

Company-level read

Ticker impact

$SEERNeutralMedium confidence
Context

Seer announced it will report Q2 2026 financial results on Aug. 11, 2026, with a webcast starting 1:30 p.m. PT.

Expected impact

Likely modest pre-earnings positioning and volatility into Aug. 11; direction depends on the upcoming results and guidance.

Evidence & confidence

The article contains no Q2 numbers or guidance, only the reporting date and webcast timing, which primarily affects timing and event-driven trading rather than fundamentals immediately.

Market effects

Limited sector read-through because the release is only a reporting-date announcement, not results or guidance.

No specific regional spillover indicated beyond event-driven trading in the US small-cap biotech/proteomics space.

No global macro or cross-border transaction details provided.

Counterpoint

Because the disclosure lacks any new financial metrics or guidance, traders may treat it as routine and focus on other catalysts rather than pre-positioning aggressively.

Key entities

  • Seer, Inc.

    Nasdaq-listed proteomics company disclosing its Q2 2026 results date and webcast time.

Related articles

$SEERMedAI 8/10

Two Revised, Non-Binding Proposals Seek to Acquire All of Seer's Class A Shares

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D. Rhea-AI Summary Seer (Nasdaq: SEER) confirmed receipt of two further revised, unsolicited, non-binding acquisition proposals for all outstanding shares of its Class A common stock. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right.

$SEERMed

Seer Stock Surges 40% After Investor Presentation Highlights AI, Growth Strategy

Seer, Inc. (SEER) shares rose about 39.8% to $2.27 on Monday after the company published an investor presentation ahead of its July 28 annual meeting. Seer cited an AI-driven proteomics strategy, commercialization progress, an expanding installed base, strategic collaborations, about $220M cash with no debt, and a stated $23B proteomics market opportunity by 2034, and urged shareholders to reject activist proposals.

$SEERMed

Seer Shares Rally 30% Following Investor Update Ahead of Annual Meeting (SEER)

Seer, Inc. (NASDAQ:SEER) shares rose about 30% after the company filed an investor presentation ahead of its July 28, 2026 annual meeting. Seer cited a $23B proteomics TAM by 2034, 62% CAGR growth in installed customers since 2021, 36% lower annual cash burn since 2022, ~$220M cash and no debt, and a $50M buyback authorization. A proxy contest is ongoing.